[go: up one dir, main page]

MX2013011421A - Derivados de pirazolo-pirimidina. - Google Patents

Derivados de pirazolo-pirimidina.

Info

Publication number
MX2013011421A
MX2013011421A MX2013011421A MX2013011421A MX2013011421A MX 2013011421 A MX2013011421 A MX 2013011421A MX 2013011421 A MX2013011421 A MX 2013011421A MX 2013011421 A MX2013011421 A MX 2013011421A MX 2013011421 A MX2013011421 A MX 2013011421A
Authority
MX
Mexico
Prior art keywords
pyrimidine derivatives
pyrazolo pyrimidine
diseases
pyrazolo
angiogenesis
Prior art date
Application number
MX2013011421A
Other languages
English (en)
Inventor
Zhengming Du
Rajender Reddy Leleti
Yugang Liu
Wolfgang Miltz
Berndt Oberhauser
Andrea Vaupel
Juraj Velcicky
Klaus Weigand
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2013011421A publication Critical patent/MX2013011421A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)

Abstract

La presente invención se refiere a derivados de pirazolo-pirimidina, a métodos para su preparación, a combinaciones y composiciones farmacéuticas que los comprenden, y a su uso en el tratamiento de enfermedades y trastornos que, por ejemplo, pueden involucrar enfermedades autoinmunes, angiogénesis, dolor, y/o enfermedades inflamatorias.
MX2013011421A 2011-04-01 2012-03-30 Derivados de pirazolo-pirimidina. MX2013011421A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161470630P 2011-04-01 2011-04-01
PCT/IB2012/051554 WO2012131633A1 (en) 2011-04-01 2012-03-30 Pyrazolo pyrimidine derivatives

Publications (1)

Publication Number Publication Date
MX2013011421A true MX2013011421A (es) 2013-12-09

Family

ID=45976462

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011421A MX2013011421A (es) 2011-04-01 2012-03-30 Derivados de pirazolo-pirimidina.

Country Status (17)

Country Link
US (1) US8748435B2 (es)
EP (1) EP2694513B1 (es)
JP (1) JP5963843B2 (es)
KR (1) KR20140023331A (es)
CN (1) CN103502248B (es)
AR (1) AR085750A1 (es)
AU (1) AU2012235665A1 (es)
BR (1) BR112013025001A2 (es)
CA (1) CA2831929A1 (es)
EA (1) EA201391440A1 (es)
ES (1) ES2534444T3 (es)
MX (1) MX2013011421A (es)
PL (1) PL2694513T3 (es)
PT (1) PT2694513E (es)
TW (1) TW201245203A (es)
UY (1) UY33976A (es)
WO (1) WO2012131633A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014049514A1 (en) * 2012-09-25 2014-04-03 Novartis Ag Compounds for use in gastric complication
CN105037373B (zh) * 2015-07-13 2018-07-31 北京理工大学 一种合成吡唑并[3,4-d]嘧啶类化合物的方法
MY186368A (en) * 2015-07-20 2021-07-16 Genzyme Corp Colony stimulating factor-1 receptor (csf-1r) inhibitors
CN108084186B (zh) * 2016-11-16 2021-06-25 江苏新元素医药科技有限公司 Urat1抑制剂及其应用
GB201700692D0 (en) * 2017-01-16 2017-03-01 Salvensis Novel compounds and their use in the treatment of schistosomiasis
EP3634417B1 (en) * 2017-05-17 2023-07-12 Arcus Biosciences, Inc. Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders
WO2020175680A1 (ja) * 2019-02-28 2020-09-03 国立大学法人大阪大学 タンパク質及び／又はペプチド修飾用分子
EP4267573A1 (en) 2020-12-23 2023-11-01 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors
CN115304607B (zh) * 2022-07-06 2023-06-27 华南农业大学 吡唑并嘧啶衍生物的制备方法
WO2025120242A1 (en) 2023-12-07 2025-06-12 Amphilix Ag Chimeric radiopharmaceuticals targeting the proton sensing receptor gpr4

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2057089A1 (en) 1990-12-07 1992-06-08 Eric E. Allen Substituted pyrazolopyrimidines and imidazopyridazines as angiotensin ii antagonists
FR2690442A1 (fr) 1992-04-27 1993-10-29 Union Pharma Scient Appl Nouveaux dérivés de pyrazolopyrimidine antagonistes des récepteurs à l'Angiotensine II; leurs procédés de préparation, compositions pharmaceutiques les contenant .
JPH069638A (ja) 1992-06-19 1994-01-18 Ube Ind Ltd ピラゾロピリミジン誘導体
DE4333705C2 (de) 1993-10-02 2003-10-30 Guenter Ege Arylmethylsubstituierte Pyrazolo-azine, insbesondere 3-Arylmethylpyrazolo[1,5-a]pyrimidine und Verfahren zur Herstellung von 8-Arylmethyl-pyrazolo[5,1-c][1,2,4]triazinen
JP3163412B2 (ja) * 1994-06-21 2001-05-08 株式会社大塚製薬工場 ピラゾロ〔１，５−ａ〕ピリミジン誘導体
CA2291709A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
US20020041880A1 (en) 2000-07-05 2002-04-11 Defeo-Jones Deborah Method of treating cancer
GB0016787D0 (en) 2000-07-07 2000-08-30 Pfizer Ltd Compounds useful in therapy
US20020107197A1 (en) 2000-09-20 2002-08-08 Yan Xu Ligands for G protein coupled receptors and methods of using them
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US7662826B2 (en) 2002-04-23 2010-02-16 Shionogi & Co., Ltd. Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same
AU2003240589A1 (en) 2002-05-14 2003-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 4 (gpr4)
EP1537879A4 (en) 2002-08-22 2007-08-15 Kyowa Hakko Kogyo Kk MEANS FOR THE PREVENTION AND / OR TREATMENT OF ASTHMA
US20060252679A1 (en) 2002-08-22 2006-11-09 Mayumi Saki Preventive and/or trerapeutic drgs for itch
EP1724271A4 (en) * 2004-02-26 2013-01-23 Kyowa Hakko Kirin Co Ltd PREVENTIVE AND / OR THERAPEUTIC AGENT AGAINST NEUTROPHIC INFLAMMATORY DISEASE
EP1731505B1 (en) * 2004-03-30 2015-01-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
US7456289B2 (en) 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
JP2009502734A (ja) 2005-07-29 2009-01-29 アステラス製薬株式会社 Ｌｃｋ阻害剤としての縮合複素環
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
MX2009005358A (es) * 2006-11-23 2009-06-05 Novartis Ag Derivados de 5-sulfanilmetil-pirazolo[1,5-a]pirimidin-7-ol como antagonistas de cxcr2.
JP2010513246A (ja) 2006-12-15 2010-04-30 ノバルティス アーゲー Ｇｐｒ４の阻害
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
CA2695989A1 (en) 2007-08-10 2009-02-19 Glaxosmithkline Llc Certain nitrogen containing bicyclic chemical entities for treating viral infections
US20090291942A1 (en) 2008-05-26 2009-11-26 Ivan Cornella Taracido Imidazo pyridine derivatives
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
US8207139B2 (en) 2009-09-15 2012-06-26 Li Yang Function of GPR4 in vascular inflammatory response to acidosis and related methods

Also Published As

Publication number Publication date
JP5963843B2 (ja) 2016-08-03
EP2694513B1 (en) 2015-01-07
JP2014514293A (ja) 2014-06-19
EA201391440A1 (ru) 2014-03-31
US8748435B2 (en) 2014-06-10
KR20140023331A (ko) 2014-02-26
PL2694513T3 (pl) 2015-06-30
WO2012131633A1 (en) 2012-10-04
CA2831929A1 (en) 2012-10-04
AR085750A1 (es) 2013-10-23
TW201245203A (en) 2012-11-16
BR112013025001A2 (pt) 2017-01-17
US20120252778A1 (en) 2012-10-04
EP2694513A1 (en) 2014-02-12
CN103502248B (zh) 2015-03-11
ES2534444T3 (es) 2015-04-23
PT2694513E (pt) 2015-04-09
UY33976A (es) 2012-10-31
CN103502248A (zh) 2014-01-08
AU2012235665A1 (en) 2013-10-10

Similar Documents

Publication Publication Date Title
MX2013011421A (es) Derivados de pirazolo-pirimidina.
PH12019502269A1 (en) Quinazoline derivatives for the treatment of viral infections and further diseases
PH12015500988B1 (en) Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
HK1214823A1 (zh) 作為jak抑制劑的三環稠合噻吩衍生物
GB201209613D0 (en) New compounds
PH12015500758A1 (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
MX349004B (es) Nuevos compuestos.
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
PH12015502780A1 (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
MX366899B (es) Nuevos compuestos.
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
PH12016500978A1 (en) Piperazine derivatives having multimodal activity against pain
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
MX2014000963A (es) Derivados de carboxamida y urea aromaticos biciclicos sustituidos como ligandos del receptor de vanilloide.
PH12015502564B1 (en) Pyridone derivatives for the treatment of viral infections and further diseases
HK1210173A1 (en) Substituted 6-amino-nicotinamides bearing an oh-containing group as kcnq2/3 modulators
IN2013MU03429A (es)
WO2014082738A8 (en) Heteroquinoline-3-carboxamides as kcnq2/3 modulators

Legal Events

Date Code Title Description
FA Abandonment or withdrawal